What is the role of edoxaban (Savaysa) in the treatment of deep venous thrombosis (DVT)?

Updated: Jun 06, 2019
  • Author: Kaushal (Kevin) Patel, MD; Chief Editor: Barry E Brenner, MD, PhD, FACEP  more...
  • Print
Answer

Edoxaban (Savaysa) was approved by the FDA in January 2015 for the treatment of DVT and PE in patients who have been initially treated with a parenteral anticoagulant for 5-10 days. [131] Approval was based on the Hokusai-VTE study that included 4,921 patients with DVT and 3,319 patients with PE. [131, 132]


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!